The Significance of Dysbiosis in the Gut Microbiome to HCV Infection and Disease Progression

Sadia Haque Khan*

Impact of Gut microbiome dysbiosis in HCV infection and disease progression

Abstract

With the development of science and technology, the amazing function of gut microbiota is being understood more and more each day. A person's physiological, metabolic, and even mental health are all touched by a tiny imbalance in the intestinal microbial community. It has been suggested that such microbiome dysbiosis contributes to the development of a variety of microbial infections, including bacterial, fungal, parasitic, and even viral infections. Throughout time, quite a few connections between gut microbiota and other parameters were found. The significance of the gut microbiome in hepatitis C virus (HCV) infection and disease development is the main topic of this review study. Millions of individuals are affected by HCV worldwide, which is a serious public health issue. Recent research has demonstrated that the pathophysiology of HCV infection and its associated illnesses, such as liver fibrosis, cirrhosis, and hepatocellular carcinoma, heavily depends on the status of the gut microbiome. The current state of knowledge regarding the gut microbiome and its interactions with HCV is summarized in this review, along with information on the effects of HCV on gut microbial diversity, potential mechanisms by which gut microbes affect HCV pathogenesis and the therapeutic potential of focusing on the gut microbiome in HCV-infected patients. On the contrary, it also covered how the gut microbiome can be modulated. We also talked about the shortcomings and difficulties of the current knowledge of the gut microbiota in HCV infection and proposed future research options in this area. Overall, this work highlights the significance of the gut microbiome in HCV infection and suggests that it may be a therapeutic target for HCV-related liver diseases.

Keywords: Gut microbiome, Hepatitis C, HCV Infection, Disease, Human.

References

Aly, A. M., Adel, A., El-Gendy, A. O., Essam, T. M., & Aziz, R. K. (2016). Gut microbiome alterations in patients with stage 4 hepatitis C. Gut pathogens, 8(1), 1-12.

Bajaj, J. S., Betrapally, N. S., Hylemon, P. B., Heuman, D. M., Daita, K., White, M. B., ... & Gillevet, P. M. (2015). Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology, 62(4), 1260-1271.

Baktash, Y., Madhav, N. V., Bieber, J. M., & Tzeng, T. R. (2017). The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS, 31(16), 2245-2258.

Chauhan, A., Kumar, R., Sharma, S., Mahanta, M., Vayuuru, S. K., Nayak, B., & Kumar, S. (2021). Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: A pilot study. Digestive Diseases and Sciences, 66, 873-880.

Chen, Y., Yang, F., Lu, H., Wang, B., Chen, Y., Lei, D., ... & Liu, Y. (2011). Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 54(2), 562-572.

Chen, L., Zhu, Y., Hou, X., Yang, L., & Chu, H. (2022). The role of gut bacteria and fungi in alcohol-associated liver disease. Frontiers in Medicine, 9, 840752.

Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., De Maria, S., Cartenì, M., & Nardone, G. (2012). Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 22(6), 471-476.

Cresci, G. A., & Izzo, K. (2019). Gut microbiome. In Adult short bowel syndrome (pp. 45-54). Academic Press.

DeGruttola, A. K., Low, D., Mizoguchi, A., & Mizoguchi, E. (2016). Current understanding of dysbiosis in disease in human and animal models. Inflammatory bowel diseases, 22(5), 1137-1150.

Dogra, S. K., Chung, C. K., Wang, D., Sakwinska, O., Colombo Mottaz, S., & Sprenger, N. (2021). Nurturing the early life gut microbiome and immune maturation for long term health. Microorganisms, 9(10), 2110.

Dore, G. J., Martinello, M., Alavi, M., & Grebely, J. (2020). Global elimination of hepatitis C virus by 2030: why not?. Nature medicine, 26(2), 157-160.

Fakruddin, M., Shishir, M. A., Yousuf, Z., & Khan, M. S. S. (2022). Next-Generation Probiotics-The Future of Biotherapeutics. Microbial Bioactives, 5(1):156-163.

Ferrere, G., & Loomba, R. (2020). Gut microbiome and nonalcoholic fatty liver disease. Hepatology, 71(1), 801-812.

Flint, H. J., Scott, K. P., Louis, P., & Duncan, S. H. (2012). The role of the gut microbiota in nutrition and health. Nature Reviews Gastroenterology & Hepatology, 9(10), 577-589.

Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013). Epidemiology and natural history of HCV infection. Nature reviews Gastroenterology & hepatology, 10(9), 553-562.

Heidrich, B., Vital, M., Plumeier, I., Döscher, N., Kahl, S., Kirschner, J., ... & Pieper, D. H. (2018). Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver International, 38(1), 50-58.

Honda, T., Ishigami, M., Yamamoto, K., Takeyama, T., Ito, T., Ishizu, Y., ... & Fujishiro, M. (2021). Changes in the gut microbiota after hepatitis C virus eradication. Scientific reports, 11(1), 23568.

Hsu, Y. C., Chen, C. C., Lee, W. H., Chang, C. Y., Lee, F. J., Tseng, C. H., ... & Wu, C. Y. (2022). Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents. Scientific reports, 12(1), 5481.

Iebba, V., Santangelo, F., Totino, V., Nicoletti, M., Gagliardi, A., De Biase, R. V., ... & Schippa, S. (2019). Higher prevalence and abundance of Bdellovibrio bacteriovorus in the human gut of healthy subjects. PLoS One, 14(5), e0219000.

Inoue, T., Nakayama, J., Moriya, K., Kawaratani, H., Momoda, R., Ito, K., ... & Tanaka, Y. (2018). Gut dysbiosis associated with hepatitis C virus infection. Clinical Infectious Diseases, 67(6), 869-877.

Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., ... & Wu, G. (2015). Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology, 149(1), 223-237.

Lavezzo B., Caputo A., Del Ben F., et al. (2019). The gut microbiota and hepatitis C virus-related chronic liver diseases: a microbiota targeted therapy. Nutrients. 11(9):2216.

Ley, R. E., Peterson, D. A., and Gordon, J. I. (2006). Ecological and evolutionary forces shape microbial diversity in the human intestine. Cell. 124(4):837-848.

Li, J., Sun, J., Rong, Y., Li, J., Xu, J., Feng, N., Liu, X., Zhang, D., Chen, W., Zhao, Y., Wang, F. (2020). Effect of fecal microbiota transplantation on patients with COVID-19: A randomized controlled trial. medRxiv.

Liang, T. J., & Ghany, M. G. (2013). Current and future therapies for hepatitis C virus infection. New England Journal of Medicine, 368(20), 1907-1917.

Liu, L., Liu, Z., Li, H., Cao, Z., Li, W., Song, Z., ... & Liu, Y. (2020). Naturally Occurring TPE-CA Maintains Gut Microbiota and Bile Acids Homeostasis via FXR Signaling Modulation of the Liver–Gut Axis. Frontiers in Pharmacology, 11, 12.

Lopez-Santamarina, A., Lamas, A., del Carmen Mondragón, A., Cardelle-Cobas, A., Regal, P., Rodriguez-Avila, J. A., ... & Cepeda, A. (2021). Probiotic effects against virus infections: New weapons for an old war. Foods, 10(1), 130.

Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. (2012). Diversity, stability and resilience of the human gut microbiota. Nature, 489(7415):220-30.

Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., ... & Greten, T. F. (2018). Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 360(6391), eaan5931.

Ma, Y., Liu, J., Rhodes, C., Nie, Y., & Zhang, F. (2017). Ethical issues in fecal microbiota transplantation in practice. The American journal of bioethics, 17(5), 34-45.

Malaguarnera G, Giordano M, Nunnari G, Bertino G, Malaguarnera M. (2014). Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World Journal of Gastroenterology, 20(47):16639.

Milosevic, I., Russo, E., Vujovic, A., Barac, A., Stevanovic, O., Gitto, S., & Amedei, A. (2021). Microbiota and viral hepatitis: State of the art of a complex matter. World Journal of Gastroenterology, 27(33), 5488.

Minot, S., Bryson, A., Chehoud, C., Wu, G. D., Lewis, J. D., & Bushman, F. D. (2013). Rapid evolution of the human gut virome. Proceedings of the National Academy of Sciences, 110(30), 12450-12455.

Moriishi, K., Fukuhara, T., Onishi, M., Yasui, F., Matsushita, M., Matsubara, H., ... & Koike, K. (2018). Metagenome analysis of liver microbiome in a mouse model of hepatitis C virus-associated hepatocellular carcinoma. Cancer medicine, 7(3), 1070-1082.

Nanis, G. A., Mohamed, L. S., Hassan, E., & Maii, M. N. (2019). Lactobacillus acidophilus and Bifidobacteria spp having antibacterial and antiviral effects on chronic HCV infection. African Journal of Microbiology Research, 13(5), 77-90.

Paracha, U. Z., Fatima, K., Alqahtani, M., Chaudhary, A., Abuzenadah, A., Damanhouri, G., & Qadri, I. (2013). Oxidative stress and hepatitis C virus. Virology journal, 10(1), 1-9.

Pawlotsky, J. M. (2013). Treatment of chronic hepatitis C: current and future. Hepatitis C Virus: From molecular virology to antiviral therapy, 321-342.

Ponziani, F. R., Zocco, M. A., D'Aversa, F., Pompili, M., Gasbarrini, A. (2017). Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World Journal of Gastroenterology, 23(20):4491.

Prati, D. (2006). Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. Journal of hepatology, 45(4), 607-616.

Preveden, T., Scarpellini, E., Milic, N., Luzza, F., & Abenavoli, L. (2017). Gut microbiota changes and chronic hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology, 11(9), 813-819.

Quaranta, G., Sanguinetti, M., & Masucci, L. (2019). Fecal microbiota transplantation: a potential tool for treatment of human female reproductive tract diseases. Frontiers in Immunology, 10, 2653.

Rashid, M., Shaik, I. H., Devi, S. M., & Shanmugam, M. (2013). Association of gut microbiota with host metabolism in liver cirrhosis patients. Saudi journal of gastroenterology, 19(5), 235-243.

Ren, Y. D., Ye, Z. S., Yang, L. Z., Jin, L. X., Wei, W. J., Deng, Y. Y., ... & Pan, J. S. (2017). Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology, 65(5), 1765-1768.

Rizzetto, L., Fava, F., Tuohy, K. M., & Selmi, C. (2021). Connecting the dots between the gut microbiome and liver disease: Rationale, expectations, and outcomes. Hepatology Communications, 5(3), 341-353.

Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nature reviews immunology, 9(5), 313-323.

Rowland, I., Gibson, G., Heinken, A., Scott, K., Swann, J., Thiele, I., & Tuohy, K. (2018). Gut microbiota functions: metabolism of nutrients and other food components. European journal of nutrition, 57, 1-24.

Sadiq, F. A. (2021). Is it time for microbiome-based therapies in viral infections?. Virus Research, 291, 198203.

Saeed, M., Shoaib, A., Kandimalla, R., Javed, S., Almatroudi, A., Gupta, R., & Aqil, F. (2022). Microbe-based therapies for colorectal cancer: Advantages and limitations. In Seminars in Cancer Biology (Vol. 86, pp. 652-665). Academic Press.

Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., ... & Nault, J. C. (2020). Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 52(5), 501-505.

Sehgal, R., Bedi, O., & Trehanpati, N. (2020). Role of microbiota in pathogenesis and management of viral hepatitis. Frontiers in Cellular and Infection Microbiology, 10, 341.

Sharpton, S. R. (2020). Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. In Seminars in liver disease, 40(3): 203-214.

Siddiqui, M. T., & Cresci, G. A. (2021). The immunomodulatory functions of butyrate. Journal of inflammation research, 14, 6025.

Sivakrishnan, S., & Pharm, M. (2019). Liver disease overview. World Journal of Pharmacy and Pharmaceutical Sciences, 8(1), 1385-1395.

Sultan, S., El-Mowafy, M., Elgaml, A., El-Mesery, M., El Shabrawi, A., Elegezy, M., ... & Mottawea, W. (2020). Alterations of the treatment-naive gut microbiome in newly diagnosed hepatitis C virus infection. ACS Infectious Diseases, 7(5), 1059-1068.

Szabo, G. & Bala, S. (2018). Microbiome interactions with the host immune response in liver diseases. Gut, 67(5):818-829.

Thaiss, C. A., Zeevi, D., Levy, M., Zilberman-Schapira, G., Suez, J., Tengeler, A. C., ... & Elinav, E. (2014). Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell, 159(3), 514-529.

Tilg, H., & Moschen, A. R. (2014). Microbiota and diabetes: an evolving relationship. Gut, 63(9), 1513-1521.

Vernocchi, P., Del Chierico, F., & Putignani, L. (2016). Gut microbiota profiling: metabolomics based approach to unravel compounds affecting human health. Frontiers in microbiology, 7, 1144.

WHO. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed 28 April 2023.

Wilson, I. D., & Nicholson, J. K. (2009). The role of gut microbiota in drug response. Current pharmaceutical design, 15(13), 1519-1523.

Yamashiro, K., Tanaka, R., Urabe, T., Ueno, Y., Yamashiro, Y., Nomoto, K., ... & Hattori, N. (2017). Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PloS one, 12(2), e0171521.

Yao, Y., Cai, X., Fei, W., Ye, Y., Zhao, M., & Zheng, C. (2022). The role of short-chain fatty acids in immunity, inflammation and metabolism. Critical reviews in food science and nutrition, 62(1), 1-12.

Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., ... & Ji, L. (2013). Human gut microbiota changes reveal the progression of glucose intolerance. PloS one, 8(8), e71108.

Zhang, J., Zao, X., Zhang, J., Guo, Z., Jin, Q., Chen, G., & Du, H. (2023). Is it possible to intervene early cirrhosis by targeting toll-like receptors to rebalance the intestinal microbiome?. International Immunopharmacology, 115, 109627.